MedDataX Logo

Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?

NCT ID: NCT04468802

Last Updated: 2020-07-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

32 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-01

Study Completion Date

2020-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them. Therefore present study aimed to examine the possible relationship between DTaP (diphtheria, tetanus, pertussis) and measles vaccination rates of Organization for Economic Co-operation and Development (OECD) countries and case fatality rate (CFR) caused by SARS CoV-2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-Specific Effects of Standard Titre Measles Vaccination

NCT00168662

Measles
COMPLETED PHASE4

Immunology of Non-specific Effects of Vaccine

NCT00168545

Measles Diphtheria Tetanus +1 more
COMPLETED PHASE4

The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age

NCT01306006

Mortality Vaccines
COMPLETED PHASE4

Additional Measles Vaccine at 4 Months of Age

NCT01486355

Measles Infection
UNKNOWN PHASE4

Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination

NCT00244673

Mortality Hospitalization Adverse Events
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them. Therefore present study aimed to examine the possible relationship between DTaP (diphtheria, tetanus, pertussis) and measles vaccination rates of Organization for Economic Co-operation and Development (OECD) countries and case fatality rate (CFR) caused by SARS CoV-2.A total of 32 OECD countries, of northern hemisphere, have been included in this study. Statistical analysis performed according to the CFR data of these countries based on SARS CoV-2. The CFR data calculated according to the total mortality count of a specific country for the 3-month period down from the date when first SARS CoV-2 case was observed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Measles Vaccine Mortality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Case fatality rate

Mortality rate caused by SARS CoV-2

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children vaccinated in OECD countries in northern hemisphere

Exclusion Criteria

* Non vaccinated children
* Southern hemisphere countries
* non-OECD countries
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kanuni Sultan Suleyman Training and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ramazan Guven

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istanbul Kanuni Sultan Suleyman Training and Research Hospital

Istanbul, Kucukcekmece, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KSSEAH--0965

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of Pediatric Measles Cases in 2019: Single-Center Experience
NCT05614791 COMPLETED
Measles Vaccine in HCW
NCT04357028 SUSPENDED PHASE3
Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?
NCT04445610 UNKNOWN
The Interaction Between Measles and DTP Vaccination
NCT02710045 COMPLETED NA
Measles Vaccination at Health System Contacts
NCT04220671 ENROLLING_BY_INVITATION PHASE4
Prophylactic Antibiotics in Measles
NCT00168532 COMPLETED PHASE3
Measles and BCG Vaccines for Mother and Child
NCT04899765 RECRUITING PHASE4
Trial of Additional Measles Vaccine to Reduce Child Mortality
NCT01644721 COMPLETED PHASE4
A Second Dose of Measles Vaccine (MV) in the Second Year of Life
NCT02943681 COMPLETED NA
Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children
NCT03460002 COMPLETED PHASE4
Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
NCT01668745 COMPLETED PHASE4
Early Two-dose Measles Vaccination Trial
NCT00168558 COMPLETED PHASE4
Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)
NCT05154097 UNKNOWN
Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children
NCT05758532 RECRUITING PHASE4
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
NCT06667206 RECRUITING PHASE2
Long-term Follow-up of Measles Antibodies
NCT00168571 COMPLETED PHASE4
Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
NCT01770119 RECRUITING PHASE4
Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
NCT05592756 COMPLETED
Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
NCT01602094 UNKNOWN
Intervention to Promote Childhood Vaccinations and Influence Vaccination Attitudes
NCT05425823 COMPLETED NA
Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years
NCT00891007 COMPLETED PHASE2
Measles, Mumps, and Rubella (MMR) Immunity in College Students
NCT00962819 COMPLETED
BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
NCT07005726 ENROLLING_BY_INVITATION PHASE4
Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?
NCT04658680 ACTIVE_NOT_RECRUITING PHASE4
Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial
NCT02504203 TERMINATED PHASE4